http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013172343-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3559a34a6976967ee22186e133b0ddad http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f895654c6560e67dd71adb52d593648 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2da0b2f93ee0fd55beedc67d4d50c2a7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22 |
| filingDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_708eef30f2e6a9ef9503f7a12ffcaa40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc6b59e66f505da6e52a8e4dc2432f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df8655b391e902a3d9e90fef4565050c |
| publicationDate | 2013-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2013172343-A1 |
| titleOfInvention | Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors |
| abstract | The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I: (I). In another embodiment, the compounds have a general Formula II: (II). In another embodiment, the compounds have a general Formula III: (III). Variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 7 , V, W, X, Y and Z of Formulas I, II and III are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formulas I, II and III, intermediates and processes useful for the preparation of compounds of Formulas I, II and III. |
| priorityDate | 2010-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1194.